Clinical trials: HPV InfectioN
Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)
The study evaluates if there is relationship between the kinds of bacteria living in the anus (also known as the anal microbiome) and the risk of human papillomavirus (HPV) infection or HPV-related pre-cancer (high-grade squamous…
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
- Trial name
- ULACNet-104 (NCT06651957)
- Testing
- Biospecimen Collection, Questionnaires
- Where
- 3 sites in United States, Mexico and 1 more
- Volunteers
- 217 people
- Sponsor
- University of California, San Francisco
Human Papillomavirus Infection, Anal HPV Infection
Epidemiology of Anal Human Papillomavirus Carriage in Female Solid Organ Transplant Recipients With More Than 10 Years of Immunosuppression
Anal canal cancer is primarily associated with persistent infection by high-risk human papillomavirus (HR-HPV), particularly HPV-16.
- Conditions
- Human Papillomavirus Infection, Anal HPV Infection, Human Papillomavirus 16 Infection
- Trial name
- EPAHTOS (NCT07858201)
- Testing
- Anal Self-Sampling for High-Risk HPV Detection
- Volunteers
- 190 people
- Sponsor
- University Hospital, Montpellier
WHIM, Warts
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
Background: Warts, hypogammaglobulinemia, infections and myelokathexis syndrome (WHIMs) is a rare disorder that affects the immune system. People with WHIMs can have severe infections all over their body.
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency
- Trial name
- NCT07775313
- Testing
- Busulfan, Palifermin, Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV Infection
A New Supplement for the Immune Response to HPV Infection
The purpose of this study is to evaluate whether a supplement in which ellagic acid plus annona muricata are combined, may modulate the immune response to high risk HPV infection.
- Trial name
- NCT02263378
- Testing
- ellagic acid + annona muricata
- Volunteers
- 60 people
- Sponsor
- University of Messina
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infertility, Transmission
Couples and Microbial Diversity
Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as…
- Conditions
- Infertility, Transmission, Infections
- Trial name
- CLARITY (NCT07315568)
- Volunteers
- 200 people
- Sponsor
- Tampere University Hospital
Warts
Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts
Warts are common and infectious viral diseases of the skin and are prevalent worldwide. Warts are caused by the human papilloma virus (HPV), which has more than 100 strains; some of them are known to be premalignant .Although…
- Trial name
- NCT03158168
- Testing
- Candida Antigen, Zinc Sulfate
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Human Papillomavirus Infection
Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care
This study evaluates the implementation of evidence based strategies to optimize HPV vaccination in rural primary care settings.
- Trial name
- NCT06256718
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Anal Cancer
Anal Cancer Screening Study
Background: HIV-positive men who have sex with men (MSM) have rates of anal cancer that approach those of cervical cancer in women.
- Trial name
- NCT00914537
- Where
- United States
- Volunteers
- 363 people
- Sponsor
- National Cancer Institute (NCI)
Human Papilloma Virus, Anogenital Wart
Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts
This study aims to investigate the relationship between HPV genotypes and treatment outcomes of intralesional immunotherapy of anogenital warts with the quadrivalent vaccine (Gardasil).
- Trial name
- NCT05761002
- Testing
- the Quadrivalent Vaccine (Gardasil)
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Zagazig University
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
This is a study of V501 [quadrivalent Human Papillomavirus (HPV) (Type 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine] in healthy Japanese boys. This study will consist of two periods.
- Trial name
- NCT02576054
- Testing
- V501
- Where
- Japan
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anogenital Human Papilloma Virus Infection
3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.
- Trial name
- NCT01427777
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Guangxi Center for Disease Control and Prevention
Periodontal Disease, Gingivitis and Periodontal Diseases
Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals With Periodontal Disease
Periodontal disease is a chronic inflammatory condition of the tooth-supporting tissues in which the host inflammatory response drives the destruction of alveolar bone and periodontal attachment.
- Conditions
- Periodontal Disease, Gingivitis and Periodontal Diseases, Biomarker Discovery and Validation, Pathways
- Trial name
- BYHN-GCF-HIPPO (NCT07759466)
- Testing
- ELISA Biomarker Analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Inonu University
Condyloma
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
- Trial name
- NCT02724254
- Testing
- AP611074 5% gel
- Where
- 12 sites in Argentina, Chile and 2 more
- Volunteers
- 218 people
- Sponsor
- Vaxart
Papillomavirus Infection, Transsexualism
HPV Prevalence in Transpersons - a Prospective Study
In this study, Human Papilloma Virus (HPV) prevalence will be determined once in the urine of 200 trans people. In addition, subjects will be asked to complete a questionnaire about their sexual orientation, which is adapted from…
- Trial name
- NCT04864951
- Testing
- Colli-Pee urine collection device, Survey
- Where
- 2 sites in Austria, Slovenia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Sophie Pils
Human Papillomavirus Infection, Cervical Cancer
Feasibility and Acceptability of HPV Self-Collection Cervical Cancer Screening and Treatment in Botswana
Aims of the Study: To assess feasibility and acceptability of introducing HPV testing of self-collected vaginal specimens (self-collection for HPV) of women age 30-49 years, followed by visual assessment of the cervix for…
- Trial name
- NCT03345875
- Testing
- HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment
- Where
- 5 sites in Botswana
- Volunteers
- 1,022 people, healthy volunteers welcome
- Sponsor
- Jhpiego
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Condylomata Acuminata
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT06197802
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00849381
- Testing
- GSK580299, GSK Biological's HPV vaccine
- Where
- 9 sites in Brazil, Taiwan and 1 more
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline